Big Pharma drools after $25B market for pricey pet care

We all know that pet owners are increasingly willing to shell out big bucks for their animal friends. Memory-foam beds for $100-plus, designer collars and leashes, that weekly hair appointment--and, yes, veterinary care. In fact, the market for pet healthcare, including drugs and flea treatments and so on, was worth about $25 billion last year.

That's one reason why so many drugmakers are investing in animal health. Dog and cat products account for the lion's share of that spending--at $9.7 billion and $4.8 billion, respectively, The Wall Street Journal reports.

Pharma companies want their share. Bayer's animal health business bought Teva Pharmaceutical Industries' ($TEVA) vet-drugs unit for $145 milion last year. Sanofi's ($SNY) Merial division recently snapped up an Indian animal health business. And, of course, Pfizer's ($PFE) Zoetis recently raised more than $2.2 billion in an IPO. Even store-brand specialist Perrigo is getting in on the action, with two buyouts--including one to the tune of $285 million--adding over-the-counter pet remedies to its portfolio.

And pet healthcare isn't just about vaccinations, routine surgeries and antibiotics. It's not even limited to old-style chemo for cancers. Pets are getting some of the high-tech oncology treatments their owners would, including tyrosine kinase inhibitors. Zoetis developed a TKI drug--Palladia--specifically for dogs, the WSJ notes. Pets are also getting heart drugs originally meant for humans.

- read the WSJ piece (sub. req.)

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.